Meloxicam Tablet
Product Images NDC 76282-153

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Meloxicam (NDC 76282-153). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Exelan Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

7.5mg-100 (Mm1)

Meloxicam 7.5 mg oral tablets packaging label from Exelan Pharmaceuticals Inc. The label states 'Meloxicam Tablets USP' with a strength of 7.5 mg, a package size of 1000 tablets, and is for prescription use only. Storage instructions indicate 20° to 25°C controlled room temperature. The label includes the NDC 76282-152-10 and cautions to keep the drug out of reach of children. It also mentions pharmacist dispensing requirements and lists the manufacturers, Ascent Pharmaceuticals and Exelan Pharmaceuticals.*

FDA Label Image

15mg-100 (Mm2)

Label for Meloxicam Tablets USP 15 mg oral tablets, containing 1000 tablets. The label includes storage instructions, dosage advisory, and states the product is Rx only. Manufactured for Exelan Pharmaceuticals Inc., with the labeler and NDC 76282-153-10 also displayed.*

FDA Label Image

Chemical Structure (Mm3)

Chemical structure of Meloxicam shown as a molecular diagram with rings, sulfur, oxygen, nitrogen, and methyl groups.*

FDA Label Image

Tab1ab (Tab1ab)

A data table presenting the percentage of adverse events occurring in 2% or more of Meloxicam patients during 4 to 12-week placebo- and active-controlled trials for osteoarthritis and rheumatoid arthritis. The table compares placebo, Meloxicam 7.5 mg daily, Meloxicam 15 mg daily, and Diclofenac or placebo groups across various disorders, including gastrointestinal, nervous system, respiratory, skin, and others.*

FDA Label Image

Tab2 (Tab2)

A text panel listing adverse reactions organized by body system for Meloxicam tablets, including various cardiovascular, gastrointestinal, psychiatric, respiratory, skin, and urinary system reactions, among others. The panel summarizes potential side effects without dosing or indication details.*

FDA Label Image

Tab3 (Tab3)

A text panel listing drug interactions for Meloxicam, detailing clinical impacts and recommended interventions when used concomitantly with various drugs including anticoagulants, aspirin, ACE inhibitors, diuretics, lithium, methotrexate, cyclosporine, NSAIDs, and pemetrexed. It provides safety monitoring and management guidelines for these combinations.*

FDA Label Image

Tab4 (Tab4)

A data table titled "Table 4 Single Dose and Steady-State Pharmacokinetic Parameters for Oral 7.5 mg and 15 mg Meloxicam" showing pharmacokinetic parameters such as Cmax, tmax, t1/2, CL/f, and V/f for different groups including healthy male adults, elderly males and females, renal failure (fasted), and hepatic insufficiency (fasted). The table presents these values separately for 7.5 mg tablets, 15 mg capsules, and under steady state and single dose conditions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.